238 related articles for article (PubMed ID: 18463343)
21. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Huang SY; Chang CS; Tang JL; Tien HF; Kuo TL; Huang SF; Yao YT; Chou WC; Chung CY; Wang CH; Shen MC; Chen YC
Br J Haematol; 1998 Dec; 103(4):1092-5. PubMed ID: 9886325
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
23. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
Fukuda M
Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
[TBL] [Abstract][Full Text] [Related]
25. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
26. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
27. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
29. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Camacho LH; Soignet SL; Chanel S; Ho R; Heller G; Scheinberg DA; Ellison R; Warrell RP
J Clin Oncol; 2000 Jul; 18(13):2620-5. PubMed ID: 10893295
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
31. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
[TBL] [Abstract][Full Text] [Related]
32. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
34. Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Alimoghaddam K; Ghavamzadeh A; Jahani M
Am J Hematol; 2006 Sep; 81(9):720. PubMed ID: 16804937
[No Abstract] [Full Text] [Related]
35. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
36. Arsenic trioxide associated toothache.
Siderov J; Duggan J
J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
[TBL] [Abstract][Full Text] [Related]
37. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
38. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
39. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
40. Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Zhou J; Meng R; Yang BF
Chin Med Sci J; 2005 Jun; 20(2):137. PubMed ID: 16075757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
